Liminatus Pharma agrees to sell 260,001 shares in $650,002.50 private placement
LIMN•Liminatus Pharma agreed to sell 260,001 common shares at $2.50 each to a non-U.S. investor, for gross proceeds of $650,002.50. The placement is expected to close on or about November 20, 2026.
1. Private placement terms
Liminatus Pharma agreed on November 2, 2026, to sell 260,001 common shares at $2.50 each in an unregistered private placement to a non-U.S. investor. The company expects the sale to close on or about November 20, 2026, and plans to use net proceeds for working capital and general corporate purposes. It will file a resale registration statement within 60 days of closing.
